CHARLOTTE, North Carolina (GenomeWeb) – Roche this week previewed its new set of sequencing-based liquid biopsy assays for cancer research, hosting an early-access tester of the products who shared some of her data at the Association for Molecular Pathology meeting held here.

Shelly Gunn, chief medical officer of contract diagnostics organization ResearchDx (and medical director of its subsidiary Pacific Diagnostics Clinical Laboratory) introduced the new assays, which Roche has named "Avenio ctDNA kits," at a workshop on Wednesday.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.